Pharmacokinetic Analysis of Nicotinamide Riboside
Information source: Aarhus University Hospital
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Participants
Intervention: Nicotinamide riboside (Dietary Supplement)
Phase: Phase 0
Status: Completed
Sponsored by: Aarhus University Hospital
Summary
Nicotinamide riboside is a newly discovered vitamin B3. The pharmacokinetics in humans is so
far not analyzed.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Serum nicotinamide riboside
Secondary outcome: serum concentrations of metabolites of nicotinamide ribosidearea under the curve for serum nicotinamide riboside calculation of halftime of serum nicotinamide riboside calculation of C-max of serum nicotinamide riboside calculation of t-max of serum nicotinamide riboside
Eligibility
Minimum age: 18 Years.
Maximum age: 30 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- BMI 18-25, healthy, male,
Exclusion Criteria:
- liver or kidney diseases, other diseases
Locations and Contacts
Medical Research Laboratories, Aarhus University Hospital, Aarhus 8000, Denmark
Additional Information
Starting date: December 2014
Last updated: February 26, 2015
|